Findings from Jacob Jacobsen and Co-Authors Provide New Insights into Depression (Serotonin Synthesis Amplification to Augment the Therapeutic Efficacy of Serotonin Reuptake Inhibitor Antidepressants: Five Decades of Clinical Evidence).

This article focuses on recent research from Research Triangle Park, North Carolina, examining the augmentation of serotonin reuptake inhibitor (SRI) antidepressant efficacy through serotonin synthesis amplification. SRIs, including selective-serotonin reuptake inhibitors (SSRIs), increase extracellular serotonin to treat depression but often show modest, inconsistent, and delayed effects. The research reviews clinical and animal evidence suggesting that adjunctive therapies enhancing serotonin synthesis—such as serotonin precursors 5-hydroxytryptophan (5-HTP), tryptophan, methylfolate, and lithium—can improve SRI effectiveness, although no FDA-approved drugs currently use this mechanism. The study concludes that developing such adjunctive therapies could offer scalable, broad-spectrum benefits across psychiatric conditions. [Extracted from the article]